Drug Profile
Dual CCR2/CCR5 agonist - Bristol-Myers Squibb
Alternative Names: CCR2/5 dual agonist - Bristol Myers SquibbLatest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Small molecules
- Mechanism of Action CCR2 receptor agonists; CCR5-receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Cancer in Unknown
- 16 Nov 2017 Phase-I clinical trials in Cancer before November 2017 (Bristol-Myers Squibb pipeline, November 2017)